Diabetes drug study uncovers hidden genetic links to weight and cholesterol
NCT ID NCT07120828
First seen Mar 18, 2026 · Last updated May 16, 2026 · Updated 10 times
Summary
This completed study looked at how two diabetes drugs (dapagliflozin and empagliflozin) affect body weight, cholesterol, and certain genes in 260 obese people newly diagnosed with type 2 diabetes. Over six months, researchers measured changes in metabolism, inflammation, and a gene called CYP8B1 that helps process bile acids. The goal was to better understand the broader health benefits of these medications beyond blood sugar control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Epu
Erbil, Kurdistan, 44001, Iraq
Conditions
Explore the condition pages connected to this study.